Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003130 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel in Treating Women With Recurrent Solid Tumors
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00003130 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 32 participants.
The verdict
NCT00003130, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating women who have recurrent solid tumors.
Interventions
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 1997-11 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003130
The ClinicalTrials.gov registry entry for NCT00003130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paclitaxel is the first listed.
NCT00003130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003130 about?
NCT00003130 is a clinical study titled "Paclitaxel in Treating Women With Recurrent Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating women who have recurrent solid tumors.
What is the current status of trial NCT00003130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 1997-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00003130?
The interventions under investigation include: paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00003130?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.